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Outcomes of endoluminal reintervention for
restenosis after percutaneous renal angioplasty
and stenting
Mark G. Davies, MD, PhD, MBA, Wael A. Saad, MD, Jean X. Bismuth, MD, Eric K. Peden, MD,
Joseph J. Naoum, MD, and Alan B. Lumsden, MD, Houston, Tex
Background: Endovascular therapy for symptomatic atherosclerotic renal artery stenosis (ARAS) is common but is
associated with a significant restenosis rate. This study evaluates the outcomes of percutaneous endoluminal therapy for
symptomatic restenosis (>50% on angiography) after renal intervention.
Methods: We performed a retrospective analysis of records from patients who underwent endovascular intervention for
ARAS and were followed by duplex ultrasound scan between January 1990 and January 2008. Clinical benefit defined as
freedom from recurrent hypertension or renal-related morbidity (increase in persistent creatinine >20% of baseline,
progression to hemodialysis, death from renal-related causes), anatomic patency, restenosis, and patient survival were
measured.
Results:A total of 447 patients underwent 619 renal artery interventions. A total of 80 vessels restenosed with an actuarial
restenosis rate of 19% at 5 years. Of these restenoses, 65 (81%) were associated with recurrent symptoms (recurrent
hypertension 84%, or continuing deterioration in renal function 16%). Fifty-five (85%) underwent repeat angioplasty and
10 underwent bypass surgery. The remainder was observed. The 55 percutaneous interventions were performed in 51
patients (61% female, average age 62 years, range, 51-85). A total of 73% had metabolic syndrome, 58% had
hyperlipidemia, and 51% were considered diabetic; all of them had primary stenting during their first procedure. There
was a 4% technical failure rate in both groups. In the restenosis group, the presence of stent was associated with a 9%
technical failure rate, while in the absence of a stent the technical failure rate was only 3% (P< .05). At 5 years, outcomes
were equivalent between the primary and recurrent groups for survival (76  2% vs 75  8%, primary vs recurrent),
cumulative patency (82  3% vs 70  10%), freedom from restenosis (81  3% vs 81  9%), and retained clinical benefit
(44 4% vs 46 10%). By Cox proportional hazards and multivariate analysis, administration of statins were associated
with freedom from restenosis in the recurrent lesions. Statins, contralateral kidney size (>9 cm) and a>20% improvement
in baseline creatinine with 3 months were associated with freedom from recurrent symptoms. Restenosis after therapy in
recurrent lesions was significantly correlated with recurrent symptoms (Spearman r  0.4614, P < .0004).
Conclusion: Percutaneous reintervention for renal artery restenosis is safe and effective with equivalent outcomes to
primary intervention. The patients are more likely to present with recurrent hypertension and be younger and of female
gender than patients presenting for primary intervention. Functional outcomes after reintervention are equivalent to
primary intervention. (J Vasc Surg 2009;49:946-52.)Percutaneous intervention for symptomatic atheroscle-
rotic renal artery stenosis (ARAS) is considered to be safe
and to have significant benefits in the well-selected pa-
tient.1-7 Restenosis following renal angioplasty remains a
considerable drawback of both angioplasty and primary
stenting of renal artery stenosis with rates of restenosis
ranging from 15 to 20%.1-9 Restenosis is strongly corre-
lated with recurrent symptoms. The outcomes and poten-
tial interventions to treated renal restenosis remain poorly
defined. Although stent placement for renal artery stenosis
has been demonstrated to be superior to balloon angio-
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946plasty for “de novo” renal artery lesions, the outcomes for
in-stent restenosis (ISR) remains unclear. The biology of
in-stent restenosis is different than that seen after balloon
angioplasty.10 The response of a vessel to a stent is depen-
dent on the stent design, length, composition, delivery
system, and deployment technique.11 This study evaluates
the outcomes of percutaneous endoluminal therapy for
symptomatic restenosis (50% on angiography) after pri-
mary renal intervention.
METHODS
Study design. We performed a retrospective analysis
of records from patients who underwent endovascular in-
tervention for ARAS and were followed by duplex ultra-
sound scan between January 1990 and January 2008. We
specifically examined those patients who developed renal
artery restenosis and examined their outcomes. Clinical
benefit was defined as freedom from recurrent hypertension
or renal-related morbidity (increase in persistent creatinine
20% of baseline, progression to hemodialysis, death from
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patient survival were measured.
Treatment algorithm. Patients with hypertension, el-
evated serum creatinine levels, congestive heart failure, or
diminishing renal mass had one or more diagnostic study
(standard angiography [35%], magnetic resonance angiog-
raphy [MRA, 21%], computed tomography [CT] angiog-
raphy [15%], renal isotope scan [8%], or duplex ultrasound
scan [21%]) to identify the presence of renal artery stenosis.
Duplex ultrasound scan criteria to identify renal artery
stenosis has been previously described.12 In the presence of
clinical criteria defined by Rundback et al13 and a 60%
stenosis on ultrasound scan or a 50% stenosis on
MRA/CT angiography or a positive renal scan, angiogra-
phy was performed. Interventions were performed in pa-
tients with renal artery stenosis 50% by angiography
regardless of comorbidities. Patients not categorized into
the clinical criteria referenced were managed medically.
Nonfunctioning kidneys were not treated. In the presence
of bilateral disease, the clinical criteria for treatment of both
kidneys were the same as those for solitary renal artery
stenosis. Patients were followed at 6-month intervals after
the procedure. Blood pressure, serum creatinine, and num-
ber of antihypertensive medications were identified during
these intervals. Each patient had at least one duplex ultra-
sound scan within 6 months of the procedure and an
ultrasound scan every 6months thereafter to assess patency.
If the duplex ultrasound scan showed 60% stenosis and
the patient had recurrent symptoms (diastolic blood pres-
sure [BP] 90 mm Hg on 3 antihypertensive medica-
tions or a 20% rise in creatinine), angiography was per-
formed and restenosis was treated if 50%. Restenosis was
measured with reference to the normal distal vessel by
electronic calibers. Restenosis was treated by either balloon
angioplasty or repeat stenting (all balloon-expandable) and
re-entered into the follow-up protocols. No cutting bal-
loon, cryo angioplasty, or drug eluting stents were used.
Definitions. Coronary artery disease was defined as a
history of angina pectoris, myocardial infarction, conges-
tive heart disease, or prior coronary artery revasculariza-
tions. Cerebrovascular disease included a history of stroke,
transient ischemic attack, or carotid artery revasculari-
zation. Hypercholesterolemia was defined as fasting choles-
terol 200 mg/dL. Diabetes was defined as a fasting
plasma glucose110mg/dL or anHbA1c7%. Diabetics
were characterized as insulin-dependent diabetes mellitus
(IDDM) or non-insulin dependent diabetes mellitus
(NIDDM). Hypertension was defined as a systolic BP
greater than 140 mm Hg or diastolic BP greater than 90
mm Hg on three occasions during a 6-month period.
Metabolic syndrome was defined as previously described14
(insulin resistance or impaired glucose tolerance, hyperten-
sion, dyslipidemia, and abdominal obesity), with the excep-
tion of abdominal circumference, which was not routinely
recorded. We substituted a body mass index score 30.0
kg/m2 as a positive score instead of an abdominal circum-
ference 102 cm or 88 cm for male or female patients,
respectively. An elevated creatinine was defined as 1.5mg/dL on two consecutive values during a 3-month pe-
riod. Chronic renal insufficiency was defined as a persistent
serum creatinine 1.5 mg/dL for greater than 6 months.
Estimated glomerular filtration rate (eGFR) was defined as
186.3 * serum creatinine1.154 * age0.203 * 0.742 (if
female) *1.212 (if African American). The baseline serum
creatinine was the value recorded closest to the procedure.
Patients were considered to have a “nonfunctioning kid-
ney” if any two of the following local criteria used at our
institution over the time of the study weremet: (1) a duplex
ultrasound scan identified a pole-to-pole length of less than
9 cm with no renal flow in the main renal artery and
parenchymal peak systolic velocity10 cm/s; (2) surgically
or congenitally absent kidney; (3) no visible nephrogram
on contrast arteriogram. Renal Resistive Index was defined
from duplex scan imaging as (1-end-diastolic velocity/peak
systolic velocity)*100. Nephrosclerosis was defined as
grade 1: Normal intrarenal vessels, orderly progression of
branching patterns (no pruning), normal nephrogram with
distinct corticomedullary junction; grade 2: Ectasia of ar-
cuate and distal interlobular arteries, peripheral pruning,
reduced arterial volume with normal renal mass, normal
nephrogram; grade 3: Marked ectasia extending centrally,
total pruning with abrupt interlobar artery terminations,
marked reduced arterial volume with decreased renal mass,
faint absent nephrogram. An endoluminal procedural suc-
cess was a residual stenosis of 30%; failures were residual
stenosis 30%, by angiographic measurement, including
lesions unable to be dilated or crossed, and occlusion
within 30 days. A death within 30 days of the procedure was
considered procedure-related. Acute functional injury was
defined as a persistent increase in the serum creatinine of
0.5 mg/dL at 1 month after the procedure. Acute ana-
tomic renal injury was defined as renal artery dissection,
perforation, acute occlusion, renal parenchymal infarction,
and renal parenchymal perforation. Access site complica-
tion was defined as hematoma, pseudoaneurysms, arterio-
venous fistula, and vessel injury requiring percutaneous or
open intervention. Systemic complications were any new
cardiac pulmonary infectious or non-renal systemic compli-
cation that required intervention or halted discharge within
24 hours of the procedure. Response in the hypertensive
patient was defined as follows: “cured” patients were nor-
motensive (diastolic BP90mmHg and systolic BP140
mm Hg) without medications; “improved” patients were
normotensive (diastolic BP 90 mm Hg and/or systolic
BP 140 mm Hg) on the same (or reduced) number of
medications or had a diastolic BP of 15 mm Hg below
baseline with the same or reduced number of medications.
“No effect” patients had no change or inability to meet
these criteria for cure or improvement and were considered
a treatment failure. Early renal function responses to angio-
plasty were defined as follows: “cured” renal function re-
quired a serum creatinine concentration 1.5 mg/dL;
“improvement” in renal function required a 20% reduc-
tion in the serum creatinine concentration; “stable” renal
function required a 20% increase or reduction in the
serum creatinine concentration; “deterioration” in renal
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concentration.13 Stable renal function and deterioration
were considered treatment failures. Freedom from renal-
related morbidity was defined as a persistent increase in
creatinine 20% of baseline, progression to hemodialysis,
death from renal-related causes.13 In-stent restenosis is
classified on the basis of length of restenosis in relation to
stented length. Four categories of in-stent restenosis were
defined (1) focal (10 mm length), (2) diffuse (10 mm
length), (3) proliferative (10 mm length and extending
outside the stent), and (4) occlusion.15
Statistical analysis. We performed our analysis on an
“intention-to-treat” basis. Measured values are reported as
percentages or means  1 standard deviation. Survival and
clinical benefit rates are calculated using life table analysis
and reported using the Society for Vascular Surgery (SVS)
criteria. Standard errors are reported in life table analyses.
The log rank test was used to determine differences be-
tween life tables. Analyses were performed using JMP soft-
ware version 7.0 (SAS Institute, Cary, NC). The Cox
proportional hazards model was employed for time-
dependent outcomes. The proportional hazards assump-
tion was checked and confirmed for the significant covari-
ates using log [survival] curves.
RESULTS
Patient population. A total of 447 patients under-
went 619 renal artery interventions (Table I). Eighty vessels
restenosed with an actuarial restenosis rate of 19% at 5 years
(Fig). Sixty-five of these restenoses (81%) were associated
with recurrent symptoms (recurrent hypertension - 84% -
or continuing deterioration in renal function - 16%). Fifty-
five (85%) underwent repeat angioplasty and 10 underwent
bypass surgery. The remainder was observed. There were
no differences in indications between the primary and
recurrent procedures. Three percent of those undergoing
percutaneous transluminal angioplasty (PTA) restenosed
and 4% of those undergoing stent placements at the pri-
mary procedure restenosed. The 55 percutaneous interven-
tions were performed in 51 patients (61% female, average
age 62 years, range, 51-85). Seventy-three percent had
metabolic syndrome, 58% had hyperlipidemia, and 51%
were considered diabetic (Table I); all patients that had
primary stenting during their first procedure with the orig-
inal lesion being in the ostial (65%), proximal (24%), or
middle (11%) parts of the renal artery. Patients with reste-
nosis were more likely to be female, a younger age, and
present with recurrent hypertension (Table I). A compari-
son of the renal function, kidney size, and hemodynamics
between primary and repeat interventions are shown in
Table II. There were no significant differences noted.
Immediate outcomes (<3 months). The recurrent
lesions were found in the ostial (56%), proximal (35%),
middle (7%), and distal (2%) parts of the renal artery. The
majority of the restenotic lesions were categorized as grade
I and grade II with the remainder being grade III (Table
III). We did not treat occlusion (grade IV). While rest-
enotic lesions were treated equally by stent placement andangioplasty, stent placement was more predominant in the
primary group (Table III). There was a 4% technical failure
rate in both groups. In the restenosis group, the presence of
stent was associated with a 9% technical failure rate, while in
the absence of a stent the technical failure rate was only 3%
(P  .05). There were no deaths within 30 days and the
morbidity related to primary interventions (7%) was signif-
icantly higher than recurrent interventions (4%, P  .05).
Specific areas of morbidity are shown in Table III. With
respect to hypertension, there was a significant clinical
benefit in 40% after primary intervention and 47% after
intervention for restenosis (Table IV). Immediate renal
clinical benefit was equivalent in both groups (Table IV).
Following primary intervention, only 8% of patients treated
demonstrated immediate clinical benefit of improved or
cured renal dysfunction and 80% showed no change within
3 months of the procedure. In comparison, of the patients
presenting with restenosis, 6% of the patients treated dem-
onstrated immediate clinical benefit of improved or cured
renal dysfunction and 93% showed no change within 3
months of the procedure (Table IV).
Outcomes (>3 months). At 5 years, outcomes were
equivalent between the primary and recurrent groups for
survival (76  2% vs 75  8%, primary vs recurrent,
respectively), cumulative patency (82  3% vs 70  10%),
freedom from restenosis (81  3% vs 81  9%), and
retained clinical benefit (44  4% vs 46  10%) (Fig). In
both groups, retained clinical benefit for hypertension (93%
vs 88%, primary vs recurrent, respectively) was superior to
clinical benefit from renal-related morbidity (33% vs 38%,
primary vs recurrent respectively) (Table IV). By Cox pro-
portional hazards and multivariate analysis, administration
of statins were associated with freedom from restenosis in
the recurrent lesions while statins, contralateral kidney size
Table I. Patients characteristics, presenting symptoms,
and co-morbidities
Primary Restenosis P value
Demographics
Patients 418 51 —
Kidneys treated 543 55 —
Male 57% 39% .05
Average age (mean  SD, years) 70  10 62  19 .05
Symptoms
Hypertension 58% 72% .05




Smoking history 64% 47% .05
Coronary artery disease 54% 41% —
Congestive heart failure 32% 16% .05
Diabetes mellitus 31% 25% —
Hyperlipidemia 69% 57% —
Metabolic syndrome 72% 71% —
Cerebrovascular 26% 22% —
SD, Standard deviation.(9 cm), and a 20% improvement in baseline creatinine
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rent symptoms. Restenosis after therapy in recurrent lesions
was significantly correlated with recurrent symptoms
(Spearman r  0.4614, P  .0004).
DISCUSSION
The current study is one of the largest reports on
restenosis and shows that the actuarial restenosis rate after
primary renal artery intervention is 19% at 5 years. Reste-
nosis was more frequent in females and about 80% were
associated with recurrent symptoms. Reintervention was
safe and technically effective. At 5 years, anatomic and
Fig. a, Survival: Kaplan-Meier analysis of survival of the
disease. The number at risk at each time interval is show
shown. b, Patency: Kaplan-Meier analysis of cumulative p
for recurrent disease. The number at risk at each time in
10% are not shown. c, Restenosis: Kaplan-Meier analysis
a repeat intervention for recurrent disease. The number at
errors exceeding 10% are not shown. d, Retained Clinic
symptoms (composite of hypertension and renal related
intervention for recurrent disease on the basis of intention
presenting symptoms. The number at risk at each time in
10% are not shown.functional outcomes were equivalent. Outcomes in recur-rent lesions were influenced by statins, contralateral kidney
size (9 cm) and a 20% improvement in baseline creati-
nine within 3 months.
The biology of in-stent restenosis is different than that
seen after balloon angioplasty.10 After balloon angioplasty,
there is thrombus formation, intimal hyperplasia develop-
ment, elastic recoil, and negative remodeling. In contrast,
after stent placement, elastic recoil and negative remodel-
ing are eliminated16 and thrombus formation followed by
intimal hyperplasia development is themain contributors to
in-stent restenosis.17,18 Patients with diabetes and prior
restenosis have a higher rate of in-stent restenosis19 and
ts with a primary and a repeat intervention for recurrent
low each figure. Standard errors exceeding 10% are not
y of vessels following a primary and a repeat intervention
l is shown below each figure. Standard errors exceeding
edom from restenosis of the patients with a primary and
t each time interval is shown below each figure. Standard
nefit: Kaplan-Meier analysis of freedom from recurrent
bidity) of the patients following a primary and a repeat
eat and in those patients who showed improved or cured









tervathere is a correlation with prolonged in-stent thrombus and
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include penetration of necrotic core, malapposition, over-
lapping stent placement, excessive stent length, and bifur-
Table II. Kidney disease, creatinine levels, estimated






1 8% 8% —
2 21% 14% —
3 53% 47% —
4 16% 20% —
5 4% 14%
Functional parameters
Mean creatinine (mg/dL) 1.7  1.0 1.6  1.0 —
Mean eGFR mL/min/
1.73m2 50  35 58  36 —
eGFR 30 mL/min/
1.73m2 20% 20% —
eGFR 30-60 mL/min/
1.73m2 53% 47% —
eGFR 60 mL/min/
1.73m2 27% 33% —
Ipsilateral kidney anatomy
Mean kidney size 10.3  1.5 10.1  1.3 —
Mean resistive index 0.79  0.05 0.72  0.14 —
Mean nephrosclerosis 1.33  0.51 1.22  0.46 —
Contralateral kidney anatomy
Normal 82% 77% —
Stenosis (60%) 5% 8% —
Non-functioning 10% 12% —
Surgically absent 2% 3% —
Contralateral kidney
parameters
Mean kidney size 9.9  1.5 9.6  1.2 —
Mean resistive index 0.78  0.04 0.73  0.14 —
Mean nephrosclerosis 1.44  0.67 1.32  0.61 —
eGFR, Estimated glomerular filtration rate.
Table III. Interventions
Primary Restenosis P value
Interventions
Angioplasty 21% 40% .05
Predilation 28% 33% —
Stent placement 79% 60% .05
Contralateral intervention 37% 18% .05
Complications
Acute functional injury 19% 16% —
Anatomic injury 7% 2% .01
Access site 9% 5% .05






*No occluded vessel was intervened on.cation lesions. Blum et al9 reported an 11% restenosis rateand that reintervention resulted in a secondary patency rate
of 92%. In the Single Operator, Single Center, Renal Stent
Retrospective Study (SOCRATES), 10% of the vessels re-
quired reintervention and was best predicted by patient age
67 years, stent diameter 5.0 mm, solitary functioning
kidney, history of lower extremity peripheral artery disease,
and antecedent history of stroke.8 In the current study, 13%
of the vessels stenosed and 10% underwent reintervention.
These data are similar to the SOCRATES data. However,
while we did find that those patients who underwent rein-
tervention were younger than those undergoing primary
intervention, only 47% of the patients were 67 years. In
addition, the average vessel size in this study was 5 mm
and only 15% had a solitary kidney. Eighty-one percent of
the restenoses presented with recurrent symptoms. This
may suggest that serial duplex scan imaging in follow-up in
the presence of an adequate clinical result and no symptoms
may not be necessary in the vast majority of patients. This
study was not designed to answer this question and there
are no consensus guidelines currently available that address
this question.
In the current study, we found we were as likely to have
used repeat angioplasty as repeat stenting. At the present
time, there is no consensus on how to intervene on renal
restenosis. In a study of 34 consecutive patients (lesions)
with in-stent restenosis, repeat renal artery stent placement
demonstrated improved patency compared with balloon
angioplasty alone with a 58% reduction in recurrent in-stent
restenosis and there was a trend favoring repeat stent place-
ment.21 In a second study, it was noted that recurrent
in-stent restenosis occurred in 27% of patients within 1 year
and that the cumulative patency rates after repeat endolu-
minal intervention were 93% and 76% after 6 and 12
months, respectively.22 Several studies have reported treat-
ing renal in-stent restenosis with drug eluting stent implan-
Table IV. Outcomes
Primary Restenosis P value
Immediate hypertension
outcomes
Deterioration 1% 0% —
No change 59% 53% —
Improved 35% 42% .05
Cured 5% 5% —
Long term hypertension
outcomes
Deterioration 7% 12% —
No change 93% 88% .05
Immediate renal outcomes
Deterioration 12% 2% .01
No change 80% 93% .05
Improved 7% 4% .05
Cured 1% 2% —
Long term renal outcomes
Increase in creatinine 20% 22% —
Progression to hemodialysis 10% 9% —
Death from renal cause 3% 7% —tation,23,24 however, the data remains limited. Zeller et al24
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who presented with their second in-stent restenosis follow-
ing renal artery stenting and noted that the technical suc-
cess rate was 100%, whether treated with balloon angio-
plasty alone (21%), with stent placement (21%), covered
stent placement (18%), with a cutting balloon (9%), or with
placement of a drug eluting stent (31%). During follow-up,
36% of these lesions developed reoccurrence and it ap-
peared that treatment with a cutting balloon was the only
significant predictor of restenosis.
In the current study, 6% of patients intervened on for
restenosis demonstrated immediate improvement in their
renal dysfunction (93% remained stable) within 3 months
of the procedure and 47% showed improvement in their
hypertension. In a study of 15 patients by Bax et al,22 renal
function remained stable or improved in most patients
(80%) after repeated intervention, and hypertension was
classified as improved or cured in 47% of patients after 1
year. Our data is extended out to 5 years and uses actuarial
analysis. We only considered those patients who showed
improvement or cure of hypertension or elevated creatinine
as a success. It demonstrates that on an intention-to-treat
basis, retained clinical benefit is 44-46% at 5 years and that
therapy for hypertension is more effective long term than
that for renal dysfunction. This mirrors data we have previ-
ously reported for both endoluminal and open renal revas-
cularization1,2,25,26 with a more liberal interpretation of
clinical benefit in that patients with no effect and stable
creatinine were considered as not having been a treatment
failure. The one question with our more conservative ap-
proach to the definition of clinical benefit, is that with a
relatively high morbidity and a low clinical benefit is
whether renal intervention carries a truly positive risk-
benefit ratio.
CONCLUSION
Percutaneous reintervention for renal artery restenosis
is safe and effective with equivalent outcomes to primary
intervention. The patients are more likely to present with
recurrent hypertension and be younger and of female gen-
der than patients presenting for primary intervention.
Functional outcomes after reintervention are equivalent to
primary intervention.
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